A couple of things stand out in this PR... As p
Post# of 36537
(Total Views: 421)
Posted On: 04/06/2020 12:00:37 PM
A couple of things stand out in this PR...
So this looks like the Chinese testing has not even started yet. We are still waiting on upfront payment and licensing fee. I thought the licensing fee was to be after they had a working vaccine? Also the upfront payment was to be reimbursements of expenses as they occured, not upfront. Very confused on the wording of the contract as compared to the PRs from GNBT.
So now it looks like we are going to do our own testing (the same that would be done in China). If that is the case, will the Chinese group want to keep going with the plans? They could just wait now and see with GNBT comes up with and license it for China without doing any of the other legwork. Yes, it would then probably be at a higher price, however then they would be jumping in on a finished product rather than having to go thru all the development/testing side.
Lastly, why is it we are always looking to add our product to other company vaccines/treatments? If our vaccine works and teaches the body to protect itself, why do we need to be an add on to other companies? They get all the glory and we are always just a note at the bottom of their PRs (because we are not allowed to quote their stock symbol in our PRs...ie MRK, which would put us on their newsfeed for their investors).
Quote:
As previously reported, we have signed an agreement with a Chinese consortium to develop our Complete Vaccine for China. Since signing the agreement, Generex has developed and refined our vaccine plans and has invoiced the Chinese consortium for the upfront payment and licensing fee.
So this looks like the Chinese testing has not even started yet. We are still waiting on upfront payment and licensing fee. I thought the licensing fee was to be after they had a working vaccine? Also the upfront payment was to be reimbursements of expenses as they occured, not upfront. Very confused on the wording of the contract as compared to the PRs from GNBT.
Quote:
Generex plans to manufacture laboratory scale amounts of the EpiVax peptides linked with our Ii-Key technology to screen against blood samples from patients who have recovered from COVID-19. We are in the process of identifying hospitals and research centers that can provide us with the blood samples for peptide epitope screening. We expect this screening process to yield the best 3 to 5 Ii-Key peptides that we anticipate will make the most safe and effective vaccine for human clinical trials.
So now it looks like we are going to do our own testing (the same that would be done in China). If that is the case, will the Chinese group want to keep going with the plans? They could just wait now and see with GNBT comes up with and license it for China without doing any of the other legwork. Yes, it would then probably be at a higher price, however then they would be jumping in on a finished product rather than having to go thru all the development/testing side.
Quote:
We are also in discussions with pharmaceutical companies to include their vaccine adjuvants as part of the clinical trial design to evaluate the potential of using adjuvant in our vaccine formulation.
Lastly, why is it we are always looking to add our product to other company vaccines/treatments? If our vaccine works and teaches the body to protect itself, why do we need to be an add on to other companies? They get all the glory and we are always just a note at the bottom of their PRs (because we are not allowed to quote their stock symbol in our PRs...ie MRK, which would put us on their newsfeed for their investors).
(4)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼